Status:
COMPLETED
DeADT - Living Well With Prostate Cancer
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
US Department of Veterans Affairs
National Cancer Institute (NCI)
Conditions:
Prostate Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
The goal of this randomized de-implementation trial is to compare two strategies to reduce low-value androgen deprivation therapy (ADT) use for prostate cancer care. The aim of the study is to compare...
Detailed Description
Project Background: Prostate cancer is a leading male cancer. One in three men with prostate cancer is chemically castrated at some point with long-acting injectable drugs (i.e., androgen deprivation...
Eligibility Criteria
Inclusion
- Any provider at participating sites who prescribes ADT for prostate cancer patients
Exclusion
- Providers opting out of study
Key Trial Info
Start Date :
October 4 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06199986
Start Date
October 4 2022
End Date
April 16 2024
Last Update
June 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Ann Arbor Healthcare System
Ann Arbor, Michigan, United States, 48105